Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of TAK-828 in Healthy Subjects
NCT02706834Phase 1Completed
- Sponsor
- Takeda
- Start
- Mar 2016
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TAK-828 in inflammatory bowel disease (IBD) (11 cohorts), sponsored by Takeda. Primary endpoints: Percentage of Participants Who Experienced at Least 1 Treatment-Emergent Adverse Event, Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event and 3 more. Started Mar 2016; status: completed.
02
Drugs
TAK-828
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT02706834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02706834.